2014
DOI: 10.3389/fmicb.2014.00385
|View full text |Cite
|
Sign up to set email alerts
|

Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon

Abstract: Over one billion people worldwide are predicted to harbor Toxoplasma infection frequently with unknown lifelong health consequences. Toxoplasmosis is an important cause of foodborne, inflammatory illnesses, as well as congenital abnormalities. Ubiquitous Toxoplasma has a unique tropism for central nervous system with a mind-bugging effect and is transmitted sexually through semen. Currently available therapies are ineffective for persistent chronic disease and congenital toxoplasmosis or have severe side effec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
39
0
4

Year Published

2014
2014
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(43 citation statements)
references
References 68 publications
0
39
0
4
Order By: Relevance
“…Therapy using this drug is quite safe for a human organism, however low bioavailability of atovaquone may result in reduced effectiveness of the medicine [8,10,11]. Definitely better effects of the treatment can be observed when the drug is applied in combination with diclazuril (a triazine-based anti-coccidiosis agent), which has recently been shown in in vivo studies on infected pregnant dams [5]. Since the beginning of pregnancy, usually before the fetus gets infected with T. gondii, application of spiramycin (rovamycine) may protect from parasite transplacental transmission.…”
Section: Currently Applied Pharmacotherapy Against Toxoplasmosismentioning
confidence: 98%
See 1 more Smart Citation
“…Therapy using this drug is quite safe for a human organism, however low bioavailability of atovaquone may result in reduced effectiveness of the medicine [8,10,11]. Definitely better effects of the treatment can be observed when the drug is applied in combination with diclazuril (a triazine-based anti-coccidiosis agent), which has recently been shown in in vivo studies on infected pregnant dams [5]. Since the beginning of pregnancy, usually before the fetus gets infected with T. gondii, application of spiramycin (rovamycine) may protect from parasite transplacental transmission.…”
Section: Currently Applied Pharmacotherapy Against Toxoplasmosismentioning
confidence: 98%
“…There are a few strategies aimed at preventing congenital toxoplasmosis in children, such as suitable education, serological diagnosis before and during pregnancy as well as examination of new-born children [3]. In many European states such as Austria, France, Italy or Portugal regular monitoring of the specific antibodies level in seronegative expectant mothers is recommended, however in other countries such as Canada or the United States, routine screening is provided only for women at high risk [4,5].…”
Section: Introductionmentioning
confidence: 99%
“…Although the infection is usually asymptomatic, T. gondii is one of the most important pathogens affecting immune-compromised patients and congenitally-infected newborns (review in Dubey et al, 2012;Oz, 2014). During T. gondii's life cycle, host infection takes place either by bradyzoites released from cysts found in different tissues of chronically infected animals, especially pork and chicken, or by ingestion of oocysts that are found in water or foods contaminated by contact with the feces of young infected cats, which release sporozoites (Dubey, 2009;Jones and Dubey, 2012).…”
Section: Introductionmentioning
confidence: 99%
“…The outcome of the invasion depends on the gestation period; thus during the third trimester it may not display any worrying symptoms. Unfortunately, the seemingly normal development of a T. gondii-infected child might result in central nervous system disorders and retinochoroiditis later in life (Oz, 2014).…”
Section: Introductionmentioning
confidence: 99%